Overview
Overview
Specialized dopaminergic neural cells differentiated from UCT-WJ-MSCs, engineered to restore dopamine synthesis and secretion in neurodegenerative and neuropsychiatric conditions
FOR RESEARCH USE AND INTERNATIONAL USE ONLY | Not for clinical use in the United States
| Source & Manufacturing |
|---|
| Derived from UCT-WJ-MSCs via targeted dopaminergic differentiation |
| Floor plate induction using Shh FGF8 Wnt signaling activation followed by neuronal maturation |
| P2 expansion maximum |
| DMSO-free glucose-based cryopreservation |
| Post-thaw viability 95% |
| Markers: TH⁺ (tyrosine hydroxylase), DAT⁺ (dopamine transporter), PITX3⁺, FOXA2⁺, NURR1⁺ |
Clinical Overview
Clinical Overview
Dopamine-Secreting Neurocytes represent one of the most targeted products in regenerative neurology. These cells are specifically differentiated to recapitulate the function of substantia nigra dopaminergic neurons — the cell population devastated in Parkinson's disease and deficient in multiple neuropsychiatric conditions. They express the rate-limiting enzyme of dopamine synthesis, tyrosine hydroxylase (TH), along with the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2), enabling authentic dopamine packaging and regulated secretion. Critically, these cells also secrete neurotrophic factors (GDNF, BDNF, NGF) that protect surviving host dopaminergic neurons — providing both cell replacement and neuroprotection simultaneously. Their immune-privileged status enables allogeneic delivery without immunosuppressants; glucose-based cryopreservation preserves TH enzymatic function and dopamine synthesis capacity across freeze-thaw cycles.
Process
Mechanism of Action
Dopamine Synthesis & Secretion: TH+ cells convert tyrosine → L-DOPA → dopamine via TH and AADC enzymes. Dopamine is packaged into synaptic vesicles by VMAT2 and released upon depolarization, restoring dopaminergic tone in the striatum and prefrontal cortex.
Synaptic Integration: Transplanted dopaminergic neurocytes extend neurite projections, form synaptic-like contacts with host striatal neurons, and integrate into nigrostriatal circuitry — demonstrated in 6-OHDA Parkinson's rat models by axon outgrowth and electrophysiological coupling.
Neuroprotection via Neurotrophic Factors: Constitutive secretion of GDNF, BDNF, and NGF activates Ret/GFRα1, TrkB, and p75NTR receptors on surviving dopaminergic neurons, promoting anti-apoptotic signaling (PI3K/Akt, MAPK/ERK) and reducing neuroinflammatory destruction.
Anti-Inflammatory Action: Like their MSC parent, dopamine neurocytes modulate microglial activation through IL-10 and IDO secretion, creating a neuroprotective microenvironment that slows progressive dopaminergic neuron loss.
Exosomal Dopaminergic Cargo: Secreted exosomes carry tyrosine hydroxylase enzyme, dopamine-synthesis miRNAs (miR-132, miR-9), and GDNF — capable of crossing the blood-brain barrier and delivering therapeutic signals to dopamine-deficient regions without direct cell transplantation.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| Tyrosine Hydroxylase (TH) | Rate-limiting enzyme in dopamine synthesis; primary identity marker |
| PITX3 / FOXA2 / NURR1 | Transcription factors specifying midbrain dopaminergic identity |
| DAT (Dopamine Transporter) | Regulates dopamine reuptake; confirms functional dopaminergic phenotype |
| VMAT2 | Vesicular packaging of dopamine for regulated synaptic release |
| GDNF / BDNF / NGF | Neuroprotective factors secreted to preserve surviving host dopaminergic neurons |
| miR-132 / miR-9 | Dopaminergic circuit regulators carried in exosomal cargo |
| α-Synuclein modulation | Exosomal cargo reduces α-synuclein aggregation via protein clearance pathways |
Applications
Therapeutic Applications
- Parkinson's Disease — dopaminergic neuron replacement, motor circuit restoration, GDNF neuroprotection
- Parkinson's-Plus Syndromes (MSA, PSP, DLB) — dopaminergic support
- Dystonia — dopamine pathway normalization, basal ganglia circuit repair
- Tourette Syndrome — dopaminergic/serotonergic balance modulation
- Treatment-Resistant Depression — dopamine reward circuit restoration (combined with serotonergic approaches)
- Bipolar Disorder — dopamine dysregulation modulation
- ADHD — prefrontal cortex dopamine enhancement, executive function support
- Motor Control Disorders / Restless Leg Syndrome — central dopaminergic tone restoration
- Dopamine Deficiency Syndromes — metabolic dopaminergic insufficiencies
Evidence
Clinical & Preclinical Evidence
In 6-OHDA Parkinson's rat models, transplanted dopaminergic cells derived from UC-MSCs demonstrated significant improvement in motor function as assessed by rotarod, cylinder, and apomorphine rotation tests. Histological analysis confirmed TH+ cell survival, neurite extension into host striatum, and reduction of neuroinflammatory markers at 8 weeks post-transplantation.
A 2024 publication in Journal of Molecular Medicine synthesized AD/PD stem cell data from 2019–2024, confirming that hAD-MSC-derived exosomes exhibited neuroprotective properties in MitoPark (transgenic PD) mice, reducing α-synuclein aggregation and improving dopaminergic neuron survival through anti-inflammatory mechanisms — with direct mechanistic parallels to Akira Dopamine Neurocyte exosomal action.[1]
The validated UCT-MSC → dopaminergic neurocyte differentiation pathway (using Shh/FGF8/Wnt) produces cells expressing TH, DAT, and VMAT2 with functional calcium-evoked dopamine release confirmed by HPLC and electrochemical detection in culture — confirming authentic dopaminergic function.[2]
Glucose-based cryopreservation of TH+ cells has been validated to maintain enzymatic activity at 90% of pre-freeze levels, with post-thaw release kinetics for dopamine confirmed within physiological ranges — critical for maintaining therapeutic efficacy after shipping.
Phase I/IIa clinical investigations of dopaminergic precursor cell transplantation in PD (multiple international centers) have demonstrated tolerability of intracranial/intrathecal delivery and initial signals of motor improvement, supporting the safety profile of this cell class.[3]